The estimated Net Worth of Francois Roger Michelon is at least $1.06 Миллион dollars as of 17 May 2022. Mr. Michelon owns over 5,100 units of ENDRA Life Sciences Inc stock worth over $24,298 and over the last 8 years he sold NDRA stock worth over $59,361. In addition, he makes $978,776 as Chairman of the Board и Chief Executive Officer at ENDRA Life Sciences Inc.
Francois has made over 2 trades of the ENDRA Life Sciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 5,100 units of NDRA stock worth $969 on 17 May 2022.
The largest trade he's ever made was selling 71,519 units of ENDRA Life Sciences Inc stock on 4 December 2020 worth over $59,361. On average, Francois trades about 5,473 units every 38 days since 2017. As of 17 May 2022 he still owns at least 97,191 units of ENDRA Life Sciences Inc stock.
You can see the complete history of Mr. Michelon stock trades at the bottom of the page.
Francois Roger Michelon serves as Chairman of the Board, Chief Executive Officer of the Company. He has over 20 years of healthcare technology experience in general management, operations, strategy and marketing across the diagnostic imaging, surgical instrument and dental sectors. From 2012 to 2014, Mr. Michelon served as Vice President of Global Marketing for the 3i division of Biomet, Inc. (now Zimmer Biomet Holdings, Inc.), a provider of oral reconstruction technologies, where he was responsible for the upstream and downstream development of the division’s global portfolio. From 2004 to 2011, Mr. Michelon served as Group Director of Global Services and Visualization for Smith & Nephew plc’s Advanced Surgical Devices division, where he led in the B2B service and capital equipment sectors, and had responsibility over the financial performance of these as well. From 1997 to 2004, Mr. Michelon worked at GE Healthcare in a variety of global upstream and downstream marketing roles. Mr. Michelon received an MBA from Carnegie-Mellon University and a BA in Economics from the University of Chicago. He has also earned his Six Sigma Black Belt certification. Mr. Michelon’s extensive industry and executive experience and his intimate understanding of our business as our Chief Executive Officer, position him well to serve as a member of our Board of Directors.
As the Chairman of the Board и Chief Executive Officer of ENDRA Life Sciences Inc, the total compensation of Francois Michelon at ENDRA Life Sciences Inc is $978,776. There are no executives at ENDRA Life Sciences Inc getting paid more.
Francois Michelon is 54, he's been the Chairman of the Board и Chief Executive Officer of ENDRA Life Sciences Inc since 2015. There are 5 older and 5 younger executives at ENDRA Life Sciences Inc. The oldest executive at ENDRA Life Sciences Inc is Michael Harsh, 65, who is the Independent Director.
Francois's mailing address filed with the SEC is C/O ENDRA LIFE SCIENCES INC., 3600 GREEN COURT, SUITE 350, ANN ARBOR, MI, 48105.
Over the last 8 years, insiders at ENDRA Life Sciences Inc have traded over $893,199 worth of ENDRA Life Sciences Inc stock and bought 413,648 units worth $301,877 . The most active insiders traders include Group Ag Ubs, Capital Advisors, Llc Conra... и Alexander Y Tokman. On average, ENDRA Life Sciences Inc executives and independent directors trade stock every 61 days with the average trade being worth of $5,922. The most recent stock trade was executed by Group Ag Ubs on 27 August 2024, trading 3,715 units of NDRA stock currently worth $2,043.
endra life sciences is bringing new capabilities to ultrasound. our photo-acoustic solutions help medical researchers screen and modify disease models with unparalleled quality and speed. we’re proud to have a global installed base of leading institutions using our nexus-128 system, the only 3d imaging solution for imaging anatomy, physiology and labeled molecular targets. the nexus 128 is a preclinical photoacoustic computed tomography (ct) scanner for small animal imaging. the system is used for simple, fast, non-invasive quantification of physiological parameters such as tumor vasculature without ionizing radiation. the fully-3d imaging technology used by the nexus 128 provides increased sensitivity compared to slice-based scanners, and dynamic (4-d) photoacoustic ct scans allow for applications such as quantification of probe uptake. the nexus 128 is currently being used by top imaging laboratories around the globe.
ENDRA Life Sciences Inc executives and other stock owners filed with the SEC include: